Abstract
The increasing prevalence of both obesity and depression is becoming a significant health concern throughout the world. Evidence suggests a positive and bidirectional association between obesity and depression. It is now well established that central serotonergic system is involved in the elicitation of satiety signal and elevation of mood. Drugs that increase serotonin neurotransmission are commonly recommended for the treatment of depression. But many patients are not benefitted by these drugs, while remission rate is also not satisfactory. Serotonin based antiobesity drugs have been either withdrawn from the market or disapproved for long term use. In view of critical need for novel therapeutic targets for obesity and depression, the role of leptin is becoming increasingly important. The peptide hormone secreted by adipocytes can cross blood brain barriers to elicit satiety signal via its receptors in the hypothalamus. Emerging evidence suggests that the peptide hormone has a role in responses to stress and produces antidepressant like effects. On the other hand, both obesity and depression are often associated with higher levels of leptin in circulation suggesting insensitivity to leptin. The aim of the present article is to draw research interest towards exploring mechanism involved in leptin resistance. These studies may facilitate the development of alternative treatment strategies, beyond serotonin based drugs, for obesity depression and their comorbid condition.
Keywords: Obesity, depression, serotonin, leptin.
Current Drug Targets
Title:Drug Targets for Obesity and Depression: From Serotonin to Leptin
Volume: 17 Issue: 11
Author(s): Darakhshan Jabeen Haleem
Affiliation:
Keywords: Obesity, depression, serotonin, leptin.
Abstract: The increasing prevalence of both obesity and depression is becoming a significant health concern throughout the world. Evidence suggests a positive and bidirectional association between obesity and depression. It is now well established that central serotonergic system is involved in the elicitation of satiety signal and elevation of mood. Drugs that increase serotonin neurotransmission are commonly recommended for the treatment of depression. But many patients are not benefitted by these drugs, while remission rate is also not satisfactory. Serotonin based antiobesity drugs have been either withdrawn from the market or disapproved for long term use. In view of critical need for novel therapeutic targets for obesity and depression, the role of leptin is becoming increasingly important. The peptide hormone secreted by adipocytes can cross blood brain barriers to elicit satiety signal via its receptors in the hypothalamus. Emerging evidence suggests that the peptide hormone has a role in responses to stress and produces antidepressant like effects. On the other hand, both obesity and depression are often associated with higher levels of leptin in circulation suggesting insensitivity to leptin. The aim of the present article is to draw research interest towards exploring mechanism involved in leptin resistance. These studies may facilitate the development of alternative treatment strategies, beyond serotonin based drugs, for obesity depression and their comorbid condition.
Export Options
About this article
Cite this article as:
Haleem Jabeen Darakhshan, Drug Targets for Obesity and Depression: From Serotonin to Leptin, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450117666151209123049
DOI https://dx.doi.org/10.2174/1389450117666151209123049 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Systemic Vasculitis: An Epidemiological Perspective
Current Immunology Reviews (Discontinued) Single-cell RNA Sequencing: In-depth Decoding of Heart Biology and Cardiovascular Diseases
Current Genomics Drug Development from Natural Resource: A Systematic Approach
Mini-Reviews in Medicinal Chemistry Steroid Hybrid Systems: New Molecular Entities with Potential Therapeutical Spectrum
Current Drug Therapy Application of Stem Cells in Cardiology: Where we are and where we are Going
Current Stem Cell Research & Therapy Antitubercular and Antimicrobial Activity of NH4VO3 Promoted 1,4- Dihydropyridine Incorporated 1,3,4-trisubstituted Pyrazole
Letters in Drug Design & Discovery A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Cellular Therapy for Heart Failure
Current Cardiology Reviews Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Controlled Release Technologies for Chronotherapy: Current Status and Future Perspectives
Current Pharmaceutical Design The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Treatment of Heyde's Syndrome by Aortic Valve Replacement
Current Cardiology Reviews Impact on DNA Methylation in Cancer Prevention and Therapy by Bioactive Dietary Components
Current Medicinal Chemistry Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update
Current Pharmaceutical Design